BioCentury
ARTICLE | Clinical News

HMPL-689: Phase I started

April 18, 2016 7:00 AM UTC

Chi-Med announced that its R&D subsidiary Hutchison MediPharma Limited (HMP) began a double-blind, placebo-controlled, dose-escalation, Australian Phase I trial of 1-30 mg oral HMPL-689 in about 50 he...